These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35639349)

  • 1. H1.0 induces paclitaxel-resistance genes expression in ovarian cancer cells by recruiting GCN5 and androgen receptor.
    Kohli A; Huang SL; Chang TC; Chao CC; Sun NK
    Cancer Sci; 2022 Aug; 113(8):2616-2626. PubMed ID: 35639349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor transcriptional activity and chromatin modifications on the ABCB1/MDR gene are critical for taxol resistance in ovarian cancer cells.
    Sun NK; Kohli A; Huang SL; Chang TC; Chao CC
    J Cell Physiol; 2019 Jun; 234(6):8760-8775. PubMed ID: 30317630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor.
    Sun NK; Huang SL; Lu HP; Chang TC; Chao CC
    Oncotarget; 2015 Sep; 6(29):27065-82. PubMed ID: 26318424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response.
    Sun NK; Huang SL; Chang PY; Lu HP; Chao CC
    Oncotarget; 2014 Dec; 5(23):11939-56. PubMed ID: 25460502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.
    Huang SL; Chang TC; Chao CCK; Sun NK
    Biochem Pharmacol; 2021 Apr; 186():114456. PubMed ID: 33556340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
    Li Y; Sun J; Gao S; Hu H; Xie P
    Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the TLR4-androgen receptor axis and genistein in taxol-resistant ovarian cancer cells.
    Huang SL; Chang TC; Chao CCK; Sun NK
    Biochem Pharmacol; 2020 Jul; 177():113965. PubMed ID: 32278794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin reduces paclitaxel resistance in ovarian carcinoma cells by upregulating SNIP1 and inhibiting NFκB activity.
    Huang SL; Chang TC; Sun NK
    Biochem Pharmacol; 2023 Jun; 212():115581. PubMed ID: 37146834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.
    Liu Z; Zhu G; Getzenberg RH; Veltri RW
    J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
    Sun NK; Huang SL; Chang TC; Chao CC
    J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
    Li Y; Chen K; Li L; Li R; Zhang J; Ren W
    Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of ITGBL1 predicts poor prognosis and promotes chemoresistance in ovarian cancer.
    Song J; Yang P; Lu J
    Cancer Biomark; 2020; 27(1):51-61. PubMed ID: 31683459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
    Lee C
    Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.
    Yang YI; Lee KT; Park HJ; Kim TJ; Choi YS; Shih IeM; Choi JH
    Carcinogenesis; 2012 Dec; 33(12):2488-98. PubMed ID: 23027625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.
    Kim SH; Juhnn YS; Song YS
    Ann N Y Acad Sci; 2007 Jan; 1095():82-9. PubMed ID: 17404021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer.
    Li Y; Mizokami A; Izumi K; Narimoto K; Shima T; Zhang J; Dai J; Keller ET; Namiki M
    Prostate; 2010 Jan; 70(1):48-60. PubMed ID: 19725034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway.
    Zhang LY; Yu JY; Leng YL; Zhu RR; Liu HX; Wang XY; Yang TT; Guo YN; Tang JL; Zhang XC
    Cancer Gene Ther; 2022 Jun; 29(6):770-783. PubMed ID: 34145425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
    Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
    Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling.
    Zhang K; Song H; Yang P; Dai X; Li Y; Wang L; Du J; Pan K; Zhang T
    Cell Prolif; 2015 Apr; 48(2):249-58. PubMed ID: 25643607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.